Dogwood Therapeutics Inc. Publishes Investor Presentation Highlighting Progress in Halneuron® Phase 2b Study for Chemotherapy-Induced Neuropathic Pain and New SP16 Cancer Pain License
I'm PortAI, I can summarize articles.
Dogwood Therapeutics Inc. (NASDAQ: DWTX) has updated its research on chemotherapy-induced peripheral neuropathy (CINP) and cancer pain. The company is advancing its Phase 2b study of Halneuron®, a Nav1.7 inhibitor, focusing on pain intensity changes over four weeks. Additionally, Dogwood announced a royalty-free license for Serpin Pharma’s SP16, aimed at treating chemotherapy-related neuropathy. The Phase 1b trial of SP16 is funded by the National Cancer Institute, with an IND application expected in Q4 2025 and patient dosing in H1 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments